Dose Proportionality of Fexofenadine
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 主要终点
- Tolerability
研究概览
简要总结
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after oral administration.
详细描述
The present study was adopted to evaluate the pharmacokinetics and dose linearity of fexofenadine after administration of single oral doses of 60 to 360 mg in an open-label, five-way crossover study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •At least 18 years old and not more than 45 healthy male volunteers
- •Actual weight no more than ± 30% from ideal body weight based on sex, height, and body frame
- •Who had passed all the screening parameters
- •Free of any drug exposure known to interfere with the pharmacokinetics or assay of fexofenadine for at least 10 days prior to the study
- •Who had to be able to communicate effectively with study personnel, be literate, and able to give consent.
排除标准
- •A clinically significant abnormal physical exam, medical history, or laboratory studies
- •If they showed a sitting SBP of >140 or <100 mmHg, DBP > 90 or <60mm Hg, or a pulse rate of > 95 or < 50 beats/min at screening
- •A history of serious intolerance, allergy, or sensitivity to fexofenadine
- •The use of any prescription drug within the previous month or use of any over-the-counter medication (with the exception of acetaminophen) within the past 14 days
- •A history of blood dyscrasias
- •A history of alcohol or drug abuse within the past year
- •Donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study
- •Unable to tolerate vein puncture and multiple blood samplings
- •Any surgical/medical condition that might alter drug absorption, distribution, metabolism, or excretion
- •Cannot follow instructions, in the opinion of the investigator.
研究组 & 干预措施
fexofenadine 180 mg
Third dose strength
干预措施: fexofenadine (Drug)
fexofenadine 60 mg
First dose strength
干预措施: fexofenadine (Drug)
fexofenadine 120 mg
Second dose strength
干预措施: fexofenadine (Drug)
fexofenadine 240 mg
Fourth dose strength
干预措施: fexofenadine (Drug)
fexofenadine 360 mg
Fifth dose strength
干预措施: fexofenadine (Drug)
结局指标
主要结局
Tolerability
时间窗: Participants will be followed for the duration of study, an expected average of 5 weeks.
Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.
次要结局
未报告次要终点
研究者
Sally Helmy, PhD, CPHQ
Lecturer of Pharmaceutics, Faculty of Pharmacy
Damanhour University